$ATRC News

AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AtriCure, Inc. 2026 Q1 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55

AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript

AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone

AtriCure Q1 2026 Earnings Call Transcript

AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.053M Est

AtriCure Q1 Adj. EPS $0.00 Beats $(0.06) Estimate, Sales $141.249M Beat $139.812M Estimate

AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains?

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash

AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?

AtriCure CFO Sees 12%-14% Organic Growth in 2026 as Pain Management Adoption Accelerates

Will AtriCure’s (ATRC) 2026 Profitability Guidance Mark a Turning Point in Its Investment Narrative?

AtriCure to Participate in the Citizens Life Sciences Conference

Demystifying AtriCure: Insights From 6 Analyst Reviews

Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $53

AtriCure, Inc. Q4 2025 Earnings Call Summary

UBS Maintains Buy on AtriCure, Lowers Price Target to $55

AtriCure shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance with its midpoint above estimates. Also, the company issued FY26 EPS guidance above estimates.

This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday